IP Verse

Therapeutic Uses Of 1-[2-(2,4-Dimethyl-Phenylsulfanyl)Phenyl]Piperazine

EP2608789

H. LUNDBECK A/S
Application Number
EP11749331A
Filing Date
Aug 22, 2011
Status
Patent Maintained As Amended
Jul 19, 2024
Grant Date
Aug 21, 2024
External Links
Slate, Register

Biblio Summary

The patent EP2608789B2 was granted on Aug 21, 2024 by H. Lundbeck A/S The patent is currently Patent Maintained As Amended.

Oppositions Filed by other Companies on the Patent

The table below shows 1 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

HEXAL AGJan 11, 2018ADMISSIBLE

More Opposed Patents of H. Lundbeck A/S

The table below shows the patents of H. Lundbeck A/S that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3345604Nalmefene For Reduction Of Alcohol Consumption In Specific Target PopulationsJun 7, 20232
EP3615518Process For The Manufacture Of Vortioxetine Hbr Alpha-FormDec 15, 20211
EP3138564Nalmefene For Reduction Of Alcohol Consumption In Specific Target PopulationsJan 31, 20181

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents